Transplacental Passage of Acetaminophen in Term Pregnancy

Joshua F. Nitsche, MD, PhD1 Avinash S. Patil, MD2 Loralie J. Langman, PhD3 Hannah J. Penn4 Douglas Derleth, MD4 William J. Watson, MD5 Brian C. Brost, MD5

1 Department of Maternal–Fetal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina
2 Department of Maternal–Fetal Medicine and Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana
3 Department of Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
4 Department of Neonatology, Mayo Clinic College of Medicine, Rochester, Minnesota
5 Department of Maternal–Fetal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota

Address for correspondence Joshua F. Nitsche, MD, PhD, Department of Maternal–Fetal Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157 (e-mail: jnitsche@wakehealth.edu).


Abstract

Objective The objective of this study was to determine the maternal and fetal pharmacokinetic (PK) profiles of acetaminophen after administration of a therapeutic oral dose.

Study Design After obtaining Institutional Review Board approval and their written informed consent, pregnant women were given a single oral dose (1,000 mg) of acetaminophen upon admission for scheduled cesarean delivery. Maternal venous blood and fetal cord blood were obtained at the time of delivery and acetaminophen levels were measured using gas chromatography-mass spectroscopy. PK parameters were calculated by noncompartmental analysis. Nonparametric correlation of maternal/fetal acetaminophen levels and PK curves were calculated.

Results In this study, 34 subjects were enrolled (median, 32 years; range, 25–39 years). The median maternal weight was 82 kg (range, 62–100 kg). All but two subjects were delivered beyond 39 weeks' gestation. The median newborn birth weight was 3,590 g (interquartile range, 3,403–3,848 g). Noncompartmental analysis described similar PK parameters in the maternal ($T_{1/2}$, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments ($T_{1/2}$, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L). Paired maternal/fetal acetaminophen levels were highly correlated ($p < 0.0001$).

Conclusion Fetal acetaminophen PKs in the fetus parallels that in the mother suggesting that placental transfer is flow limited. Maternal acetaminophen levels can be used as a surrogate for fetal exposure.

Keywords ► fetal drug exposure ► acetaminophen ► pregnancy ► pharmacokinetics

Acetaminophen is taken by nearly two-thirds of pregnant women, making it the most commonly utilized over-the-counter medication in pregnancy.1 Despite the perception of safety, maternal acetaminophen use has been associated with increased risks to the newborn of attention deficit hyperactivity disorder (ADHD),2 drug-induced liver injury (DILI),3 and asthma in childhood.4 The extent of fetal exposure from a standard acetaminophen dose is not well understood. Acetaminophen has been demonstrated to cross the placenta after maternal overdose5 as well as after therapeutic doses.6 Two
case reports described fetal death after maternal overdose that resulted in maternal liver injury; however, the cause of fetal death was not definitively determined in either case.3,5 Four other reports describe cases of toxic maternal levels of acetaminophen without any documented fetal sequela.2–10 Fortunately, studies involving therapeutic doses of acetaminophen have failed to demonstrate a risk to the fetus in any trimester11 and is listed as a category B medication for use in pregnancy. In addition, a registry of more than 88,000 first-trimester exposures to acetaminophen has not shown an increase in congenital anomalies in the fetuses exposed.12 However, the possibility of altered metabolism of the drug in the fetus raises the possibility that it could accumulate to toxic levels with chronic use.

Acetaminophen is widely used in pregnancy,13 as other pain relievers such as NSAIDs or narcotic medications carry the risk of fetal harm, namely, premature closure of the ductus arteriosus and neonatal withdrawal, respectively.11 Surprisingly, search of the PubMed database for the terms “acetaminophen,” “paracetamol,” and “pregnancy” revealed only one case report describing the levels of acetaminophen in the neonate after a therapeutic maternal dose of acetaminophen.6 This report suggests that the level attained in the neonate after a single maternal dose of acetaminophen is similar to the levels obtained after an oral dose administered directly to the neonate. An experimental study of normal pregnant women undergoing scheduled cesarean delivery has also shown similar acetaminophen levels in mother and neonate as soon as 30 minutes after maternal administration.14 However, the rate of decline and duration of action of acetaminophen after placental transfer has yet to be determined. In this study, we compare the maternal and fetal pharmacokinetic (PK) profiles of acetaminophen after administration of a therapeutic oral dose.

**Study Design**

Institutional Review Board approval was obtained for a prospective study of acetaminophen PKs in term pregnant women. After obtaining written consent, women without medical or obstetrical complications were given a single oral dose (1,000 mg) of acetaminophen upon admission for scheduled cesarean delivery. At the time of delivery, 5 mL of maternal peripheral venous blood and 15 mL of fetal cord blood were obtained at the time of delivery. Acetaminophen and its deuterium labeled internal standard, acetaminophen d₄, were purchased from Cerilliant (Round Rock, TX). All solvents were high performance liquid chromatography grade or better, and all chemicals were American Chemical Society grade. Solid phase extraction was followed by derivatization using BSTFA 1% TMCS. One microliter of prepared sample was injected onto an Agilent gas chromatography-mass spectroscopy system (Agilent Technologies, Inc., Santa Clara, CA). Quantitation was performed using selected ion monitoring and concentrations were calculated based on a five-point calibration curve using a 1/x linear curve fit. The calibrators ranged from 0.50 to 15 µg/mL and were included with each analytical run. Samples > 15 µg/mL were diluted with drug-free serum and reanalyzed. Each maternal/child pair contributed one set of values to the analysis. PK parameters were calculated by noncompartmental analysis using PK solver. PK parameters assessed included maximum concentration (Cmax), area under the curve from time 0 to ∞ (AUC₀–∞), apparent volume of distribution (Vd/F), and apparent clearance (Cl/F). AUC₀–∞ represents the total amount of drug available after administration. The Vd/F and CI/F parameters illustrate the distribution of drug into body tissues and rate of elimination of drug, respectively. A linear regression was performed to determine how well maternal acetaminophen levels predicted fetal levels.

**Results**

In this study, 34 subjects were enrolled at a median age of 32 years (range, 25–39 years). Subjects were primarily Caucasian (31/34 or 91%), with the remainder Asian (2/34 or 6%) or Hispanic (1/34 or 3%). The median maternal weight was 82 kg (range, 62–100 kg). Two women delivered at 38 weeks’, 30 delivered at 39 weeks’, and 2 women delivered at 40 weeks’ gestation. The median newborn birth weight was 3,590 g (interquartile range, 3,403–3,848 g). Noncompartmental PK analysis described acetaminophen disposition in the maternal compartment with a half-life of 84 minutes and Cl/F of 28.8 L/h. In the fetal compartment, acetaminophen half-life was 82 minutes with a Cl/F of 31.2 L/h. Peak concentrations of acetaminophen (maternal 12.3 µg/mL; fetal 11.2 µg/mL) and Vd/F (maternal 57.5 L; fetal 61.2 L) were similar. Linear regression analysis revealed that maternal acetaminophen level was a significant predictor of fetal level (p > 0.0001) and that maternal and fetal levels were very highly correlated (r = 0.91). PK parameters and curves are provided in Fig. 1.
Conclusion

Acetaminophen PKs in maternal samples are consistent with values previously reported in pregnant women (Vd/F, 57.5 L; Cl/F, 28.8 L/h), except for a shorter half-life (84 vs. 114 minutes). They are also consistent with those described in healthy male volunteers in whom serum levels peak between 7.7 and 17.6 µg/mL and have a half-life of 1.5 to 2.5 hours. These values are similar to the peak concentration of 12.3 µg/mL and a half-life of 84 minutes seen in our PK model. Maternal and fetal acetaminophen levels are comparable as early as 30 minutes after administration, indicating rapid placental transfer of the drug. Notably, acetaminophen PKs in fetal samples closely parallels behavior of the drug in the maternal system. The time to peak concentration and half-life are similar, and the fetal AUC is nearly the same as maternal AUC (> 90%). The comparable concentrations of acetaminophen in the maternal and fetal compartments suggest that placental transfer is influenced primarily by rate of blood flow (“flow limited”) and not by transporters in the placenta (“diffusion limited”).

Fetal acetaminophen exposure has been associated with ADHD, DILI, and childhood asthma, though the threshold for these effects in the fetus is not known. An understanding of placental transfer kinetics is necessary to correlate maternal drug intake to fetal exposure and clinical outcomes. In this study, we have demonstrated that acetaminophen levels in the fetal compartment are nearly identical to maternal levels. The very high correlation between maternal and fetal levels suggests that maternal acetaminophen levels can be used as a surrogate for the extent of fetal exposure.

The modest sample size and lack of information on acetaminophen metabolites are the main weaknesses of the study. Although our findings do provide novel information on the PKs of acetaminophen in pregnant women and their fetuses, acetaminophen levels alone cannot provide precise estimates of fetal risk, as acetaminophen-mediated injury occurs when a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), is formed. Saturation of the metabolic enzymes that inactivate acetaminophen leads to accumulation of NAPQI and subsequent adverse effects. Thus, future studies should assess NAPQI along with acetaminophen levels and utilize a larger sample size to permit a formal population PK analysis. In addition, our observation that transplacental passage of acetaminophen is “flow limited” is based on features of the maternal and fetal PK curves. Confirmation that acetaminophen does not interact with placental transporters may be obtained through ex vivo placental perfusion studies.

Although the current study suggests that fetal exposure to acetaminophen can be predicted using maternal drug levels, further study of acetaminophen metabolism to NAPQI in the fetus is clearly needed to better understand the risk of fetal harm after maternal acetaminophen use. However, our findings suggest that maternal use of acetaminophen at the currently recommended dose is unlikely to lead to accumulation of potentially toxic levels in the fetus.

References